Stay updated on Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page
- Check3 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedSite revision label updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check46 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. It indicates a minor update to the page without changing the core study details or eligibility criteria.SummaryDifference0.0%

- Check68 days agoChange DetectedThe page now displays revision v3.4.2; the previous revision v3.4.1 has been removed.SummaryDifference0.0%

- Check75 days agoChange DetectedThe page now shows Revision: v3.4.1, replacing the previous Revision: v3.4.0.SummaryDifference0.0%

- Check89 days agoChange DetectedAdded UI/metadata updates: Show glossary, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0. Removed: Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.